Try out PMC Labs and tell us what you think. Learn More.

Eur J Rheumatol. 2019 Jul; 6(3): 146–149. PMCID: PMC6668644

Published online 2018 Jul 1. doi: 10.5152/eurjrheum.2019.19036 PMID: 31364981

Comprehensive review of current diagnostic and treatment approaches

to interstitial lung disease associated with rheumatoid arthritis
Cemal Bes

Department of Rheumatology, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research
Hospital, İstanbul, Turkey
Corresponding author.
Address for Correspondence: Cemal Bes; Department of Rheumatology, University of Health Sciences, Bakırköy
Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey, E-mail: [email protected]

Received 2019 Feb 16; Accepted 2019 May 9.

© Copyright by 2019 Medical Research and Education Association

Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International
License.

Abstract
Interstitial lung disease (ILD) is one of the extra-articular involvement forms of
rheumatoid arthritis (RA), and it is associated with increased mortality. The presence
of genetic susceptibility, smoking, rheumatoid factor positivity, and the presence of
anticitrulline peptide antibodies are factors contributing to the development of ILD in
patients with RA. Early diagnosis and treatment of ILD contribute to the reduction of
morbidity and mortality. We herein evaluated the current literature for the diagnosis
and treatment of RA-associated ILD.

Keywords: Interstitial lung disease, arthritis, life threatening

Introduction
Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease manifested by
articular and extra-articular features. Pulmonary involvement is a common extra-
articular manifestation occurring roughly in approximately 60%–80% of patients with
RA. The pulmonary involvement in RA may vary, including interstitial lung disease
(ILD), pleural disease, rheumatoid nodules, bronchiectasis, and vasculitis. ILD is one
particular type of pulmonary involvement associated with significant morbidity and
mortality (1–3). The management of RA-associated ILD (RA-ILD) depends on patients’
clinical, functional, and radiologic findings. Several therapeutic agents have been
suggested in the literature, but the optimal treatment has not been determined (4–6).

Risk factors
The mechanism behind ILD in RA is poorly understood, but there are certain risk
factors believed to play an important role. Smoking is believed to play the major role,
but male sex, high titers of the rheumatoid factor, and elevated anticyclic citrullinated
protein antibodies are the prevailing factors.

Clinical features and diagnostic tools

In 2002, the American Thoracic Society/European Respiratory Society classification of
acute and chronic parenchymal lung diseases (7) has also been adopted for the
identification of ILD (Table 1). The clinical manifestations of RA-related ILD are
dyspnea and dry cough. However, some patients may be asymptomatic, especially in
early stages. Pleuritic chest pain, fever, hemoptysis, and tachypnea are other
symptoms of the disease. The most frequent finding on physical examination were
crepitant rallies in bilateral baselines in pulmonary auscultation. In the majority of
patients, the pulmonary function test (PFT) has a low force vital capacity (FVC), low
total lung capacity, low/normal carbon monoxide diffusion capacity (DLCO), and
restrictive respiratory pattern with exercise or resting hypoxemia (8). Since the earliest
functional disorder in patients with ILD is a DLCO decrease, DLCO is one of the
important tests for the early diagnosis of ILD. FVC may not be affected until the late
stage. The PFTs may also reveal a normal or high force vital capacity at 1 second/FVC
(restrictive type lung disease finding) ratio. DLCO and FVC are the most commonly and
most important used diagnostic markers in ILD. Generally, changes of 10% in FVC and
15% in DLCO are considered to be significant (8). X-ray has a low sensitivity in the ILD
detection, and X-ray findings may be normal in early stages. Reticular and small
nodular opacities can be seen in lower lung zones on plain chest X-ray. High-resolution
computed tomography (HRCT) has been accepted as the gold standard noninvasive
imaging method in the diagnosis of ILD in patients with RA (9). HRCT results were
consistent with the results of open lung biopsy (10).

Table 1

American Thoracic Society/European Respiratory Society Classification of

Idiopathic Interstitial Pneumonia

Histologic Pattern Clinical/Radiologic/Pathologic Diagnosis

Usual interstitial pneumonia Idiopathic pulmonary fibrosis/cryptogenic fibrosing
alveolitis
Nonspecific interstitial pneumonia Nonspecific interstitial pneumonia
Organizing pneumonia Cryptogenic organizing pneumonia
Diffuse alveolar damage Acute interstitial pneumonia
Respiratory bronchiolitis Respiratory bronchiolitis interstitial lung disease
Desquamative interstitial Desquamative interstitial pneumonia
pneumonia
Lymphoid interstitial pneumonia Lymphoid interstitial pneumonia

The most common HRCT findings in patients with RA-ILD are usual interstitial
pneumonia (UIP) (Figure 1), nonspecific interstitial pneumonia (NSIP) (Figure 2),
lymphocytic interstitial pneumonia, organizing pneumonia, diffuse alveolar damage,
respiratory bronchiolitis, and desquamative interstitial pneumonia (11). Since there
may be some alterations in bronchoalveolar lavage (BAL) fluid in the absence of ILD,
BAL is not routinely used as a diagnostic tool to demonstrate the presence of ILD in RA.
Neutrophil and macrophage predominance is a characteristic feature of RA-ILD.
Although BAL may be useful in the exclusion of infection, it is not necessary for the
diagnosis of RA-ILD. Surgical lung biopsy has been considered the gold standard in the
histopathological diagnosis. However, due to the potential risks associated with the
method, many patients are diagnosed without surgical biopsy and pathologic
confirmation. Video-assisted thoracoscopic surgery is often preferred for open lung
biopsy. Transbronchial biopsy in diagnosis is limited, and it is not required in patients
with typical clinical and radiological findings.

Figure 1

Usual Interstitial Pneumonia (UIP); Peripheral Septal Thickening, Bronchiectasis, and

Honeycombing
 Figure 2

Nonspecific Interstitial Pneumonia (NSIP); Bilateral Ground-Glass Opacities with

Associated Fine Reticulations and Traction Bronchiectasis

Recent developments in diagnosis

Studies on biomarkers that can be used to confirm the diagnosis and evaluate the
treatment response are still ongoing. In recent years, a serologic marker known as KL-
6 (Krebsvon del Lungen-6, proliferating Type 2 pneumocytes and high-molecular-
weight glycoprotein expressed in epithelial cells) has been investigated. Serum KL-6
levels were elevated in interstitial pneumonia, hypersensitivity pneumonitis,
tuberculosis, sarcoidosis, and pulmonary alveolar proteinosis. It was also observed in
patients with RA-ILD (11, 12). A significant increment in the serum KL-6 levels reflects
the extensity of HRCT lesions. The grade of alveolitis and severity of pulmonary
fibrosis, however, may not be very sensitive in early-stage pulmonary disease. It can
also be helpful in the detection of active and progressive pulmonary disease in RA-ILD
(12). Oyama et al. (13) reported that KL-6 was elevated in 88.9% of patients with active
ILD, and in only 0.6% of patients without active ILD. Recently, studies indicating that
transthoracic ultrasonography is a useful method in the diagnosis of early-stage ILD
have been published. In a study involving patients with RA, systemic sclerosis, and
systemic lupus erythematosus, a significant proportion of patients who showed ILD on
HRCT also showed pathological changes in transthoracic ultrasonography (14).

The 18-flurodeoxyglucose positron emission tomography/computed tomography (18

FDG PET-CT) is an alternative method that can be used in the diagnosis of ILD. A recent
study evaluating patients with connective tissue disease reported that deep-inspiration
breath-hold 18F-FDG-PET/CT could be a useful method in the diagnosis of ILD (15).
Management
Treatment regimens must be tailored to the individual patient; both the supportive
treatment and medical treatment should be emphasized. The promotion of smoking
cessation comes at the beginning of supportive therapies, which is considered to play a
pivotal role in the pathogenesis of RA, and also known to increases both joint
symptoms and lung damage. Pneumococcal and influenza vaccines should be routinely
administered. Oxygen should be administered to patients with low oxygen saturation
(16, 17).

Treatment of RA-ILD is becoming more complicated and challenging, since almost all
drugs used in the treatment of RA can cause ILD or have already mediated ILD. Hence,
treatment depends on the severity of the disease and the clinical condition of the
patient. At this point, radiological findings and functional capacity of the lungs are as
important as the clinical condition of the patient. There are some cases where disease
symptoms are absent (e.g., breathlessness and/or cough) that are incidentally detected
with radiologic imaging of ILD findings, and these patients do not need additional
treatment if they are functionally stable (18). It is recommended to follow these
patients with the respiratory function test (PFT) every 3 months, and HRCT and
PFT/DLCO every 6–12 months for the first 2 years, if the symptoms progress. Treatment
of asymptomatic RA-associated patients with ILD without progressive disease should
be continued as usual, and the use of any DMARD that controls joint symptoms is not
contraindicated in those patients. During the follow-up period, patients in who
progression is indicated according to clinical, radiological, or PFT findings should be
given additional ILD treatment. Despite the lack of controlled studies in the RA-ILD
treatment, corticosteroids are considered as the first-line therapy. The initial dose is
usually 0.5–1 mg/kg prednisolone (usually 40–60 mg/daily). Once the response to
corticosteroids is achieved, the dose is gradually reduced to the lowest possible dose.
Some ILD subtypes, such as the NSIP and OP, have a better response to corticosteroids
than other subtypes. When corticosteroids are reduced, additional
immunosuppressive agents may be required. For this purpose, corticosteroids may be
combined with azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) (19,
20). As there is a risk of respiratory failure, patients with a rapidly progressive ILD
pattern should be approached aggressively.

Corticosteroids at high doses (prednisolone at 10 mg/kg/day) and intravenous pulse

cyclophosphamide (6 cycles at 15 mg/kg) every 3–4 weeks are recommended in these
patients. At the end of the cyclophosphamide treatment, MMF or azathioprine therapy
are recommended as an indwelling therapy. Cyclophosphamide has been reported to
be useful in active, rapidly progressing disease (19), although there are no randomized
controlled trials of its use in RA-ILD, and limited efficacy has been reported. In a cohort
of mixed connective tissue diseases involving a small number of patients with RA-ILD,
it has been reported that mycophenolate mofetil contributes to symptomatic recovery
and stabilization or improvement in PFTs, and it is also useful in reducing steroid
doses (20, 21). Although few studies have shown positive effects on lung findings, since
there is no curative effect on joint symptoms, the use of mycophenolate mofetil is
limited.

Rituximab (RTX) has been one of the most commonly used drugs in the treatment of
RA-ILD in recent years. It is a monoclonal antibody against the B-cell marker CD20
used to treat patients with RA who do not respond to anti-TNF therapy or who cannot
use these drugs. After the demonstration of follicular B-cell hyperplasia and interstitial
plasma cell infiltration in patients with RA-ILD, a potential role of B-cells in
pathogenesis is suggested. This led to an increased interest in RTX for the treatment of
RA-ILD (22, 23). In contrast to other biological therapies, there is a concern about the
potential pulmonary RTX toxicity. The reported cases are largely due to
lymphoproliferative diseases. However, there are several reports on the development
or worsening of ILD in RA patients using rituximab (24–26). It has been shown that
antitumor necrosis factor (anti-TNF) agents have great efficacy in the suppression of
RA joint symptoms and improvement of the disease progression, and they have been
used in many RA patients who have not responded to conventional DMARD therapy in
recent years.

However, with the widespread use of these drugs, they have caused concerns about
potential pulmonary toxicity. There have been reports of new-onset ILD or worsening
of preexisting disease after starting an anti-TNF treatment (27–31). In a study by
Ramos-Casals et al. (32), it was reported that ILD develops in 10% of 226 patients (83%
of RA) who received anti-TNF therapy.

On the other hand, some studies show that there is no correlation between the use of
anti-TNF and the development or exacerbation of ILD in RA. A report from the British
Society for Rheumatology Biologics Register on patients with RA-ILD taking either anti-
TNF agents or traditional DMARDs showed no difference in mortality rates. However,
in the same report, the ILD mortality was 21% in patients treated with anti-TNF
therapy compared to 7% in conventional DMARDs (33). In another study, Herrinton et
al. (34) compared anti-TNF therapy with non-TNF biologic therapy in their study of
more than 8.000 patients; there was no difference in the development of ILD.

However, anti-TNF drugs have been shown to have potentially positive effects in
stabilizing or ameliorating pulmonary disease (35). Experimental studies indicate that
TNF-alpha may have both profibrotic and antifibrotic effects; the imbalance between
these two roles may trigger fibrosis or stable ILD in vulnerable individuals, but further
studies are needed to confirm this hypothesis (36). Patients with preexisting RA-ILD
should be followed closely during anti-TNF treatment. Since methotrexate has a
potential risk of pulmonary toxicity, the combination of anti-TNF and methotrexate
may have a greater risk of developing ILD or worsening the preexisting disease.
Therefore, in patients with ILD, the combination of methotrexate and anti-TNF should
not be preferred or should be closely monitored in case of necessity. Although the non-
TNF biological agents such as tocilizumab and abatacept are reported to be beneficial
in RA patients with ILD, there are some reports that suggest new ILD developments or
worsening of the preexisting ILD under these agents (37–40). Lung transplantation is
recommended as an option in case of progressive and severe pulmonary disease,
despite medical treatment.

Prognosis
Patients with RA-associated ILD have an increased mortality compared to patients
without ILD. The male sex, an advanced age, high seropositivity, and greater
impairment of the pulmonary function at diagnosis have been associated with worse
prognosis (30). Histopathologic and/or radiologic phenotype plays an important role in
the prognosis of RA-associated ILD. The cases with the UIP pattern have a worse
prognosis compared to those without the UIP pattern (3, 11).

Conclusion
Interstitial lung disease is a common extra-articular manifestation of RA, associated
with increased morbidity and mortality. At baseline, an assessment of the severity and
the extent of ILD using objective pulmonary parameters is required to make decisions
with regard to therapy. The treatment of RA-associated ILD should be tailored for each
patient. It should also be kept in mind that drugs used for RA may exacerbate ILD.

Footnotes
Peer-review: Externally peer-reviewed.

Conflict of Interest: The author has no conflict of interest to declare.

Financial Disclosure: The author declared that this study has received no financial support.

References
1. Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al.
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit
Care Med. 2011;183:372–8. doi: 10.1164/rccm.201004-0622OC. [PMC free article]
[PubMed] [CrossRef] [Google Scholar]

2. Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep.
2010;12:363–9. doi: 10.1007/s11926-010-0116-z. [PubMed] [CrossRef] [Google Scholar]

3. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Uden JHV, et al. Usual
interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur
Respir J. 2010;35:1322–8. doi: 10.1183/09031936.00092309. [PubMed] [CrossRef]
[Google Scholar]

4. Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease
and airway disease in rheumatoid arthritis. Respir Med. 2012;106:1591–9.
doi: 10.1016/j.rmed.2012.07.006. [PubMed] [CrossRef] [Google Scholar]

5. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur Respir J.
2005;25:915–27. doi: 10.1183/09031936.05.00133404. [PubMed] [CrossRef]
[Google Scholar]

6. Saag G, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al.
Rheumatoid arthritis lung disease: Determinants of radiographic and physiologic
abnormalities. Arthritis Rheum. 1996;39:1711–9. doi: 10.1002/art.1780391014. [PubMed]
[CrossRef] [Google Scholar]

7. American Thoracic Society; European Respiratory Society. American Thoracic

Society/European Respiratory Society International Multidisciplinary Consensus
Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the
American Thoracic Society (ATS), and the European Respiratory Society (ERS) was
adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee,
June 2001. Am J RespirCrit Care Med. 2002;165:277–304. doi: 10.1164/ajrccm.165.2.ats01.
[PubMed] [CrossRef] [Google Scholar]

8. Behr J, Furst DE. Pulmonary Function Tests. Rheumatology (Oxford) 2008;47(Suppl

5):v65–7. doi: 10.1093/rheumatology/ken313. [PubMed] [CrossRef] [Google Scholar]

9. Biederer J, Schnabel A, Muhle C, Gross WL, Heller M, Reuter M. Correlation between

HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in
interstitial lung disease associated with rheumatoid arthritis. Eur Radiol. 2004;14:272–
80. doi: 10.1007/s00330-003-2026-1. [PubMed] [CrossRef] [Google Scholar]

10. Salaffi F, Manganelli P, Carotti M, Baldelli S. The differing patterns of subclinical

pulmonary involvement in connective tissue diseases as shown by application of factor
analysis. Clin Rheumatol. 2000;19:35–41. [PubMed] [Google Scholar]

11. Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al.

Lung diseases directly associated with rheumatoid arthritis and their relationship to
outcome. Eur Respir J. 2011;37:1411–7. doi: 10.1183/09031936.00019210. [PubMed]
[CrossRef] [Google Scholar]

12. Kinoshita F, Hamano H, Harada H, Kinoshita T, Igishi T, Hagino H, et al. Role of KL-6
in evaluating the disease severity of rheumatoid lung disease: comparison with HRCT.
Respir Med. 2004;98:1131–7. doi: 10.1016/j.rmed.2004.04.003. [PubMed] [CrossRef]
[Google Scholar]
13. Oyama T, Kohno N, Yokoyama A, Hirasawa Y, Hiwada K, Oyama H, et al. Detection
of interstitial pneumonitis in patients with rheumatoid arthritis by measuring
circulating levels of KL-6, a humanMUC1 mucin. Lung. 1997;175:379–85.
doi: 10.1007/PL00007584. [PubMed] [CrossRef] [Google Scholar]

14. Moazedi-Fuerst FC, Kielhauser S, Brickmann K, Tripolt N, Meilinger M, Lufti A, et al.

Sonographic assessment of interstitial lung disease in patients with rheumatoid
arthritis, systemic sclerosis and systemic lupus erythematosus. Clin Exp Rheumatol.
2015;33:87–91. [PubMed] [Google Scholar]

15. Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A, et al. Deepinspiration

breath-hold 18F-FDG-PET/CT is useful for assessment of connective tissue disease
associated interstitial pneumonia. Mod Rheumatol. 2016;26:121–7.
doi: 10.3109/14397595.2015.1054099. [PubMed] [CrossRef] [Google Scholar]

16. Demoruelle MK, Mittoo S, Solomon JJ. Connective tissue disease-related interstitial
lung diseases. Best Pract Res Clin Rheumatol. 2016;30:39–52.
doi: 10.1016/j.berh.2016.04.006. [PubMed] [CrossRef] [Google Scholar]

17. Aparicio IJ, Lee JS. Connective tissue disease-associated interstitial lung diseases:
unresolved Issues. Semin Respir Crit Care Med. 2016;37:468–76. doi: 10.1055/s-0036-
1580689. [PubMed] [CrossRef] [Google Scholar]

18. Mathai SC, Danoff SK. Management of interstitial lung disease associated with
connective tissue disease. BMJ. 2016;352:h6819. doi: 10.1136/bmj.h6819.
[PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Chan E, Chapman K, Kelly C. Interstitial lung disease in rheumatoid arthritis: a

review. Arthritis Research UK; 2013. [Google Scholar]

20. O’Dwyer DN, Armstrong ME, Cooke G, Dodd JD, Veale DJ, Donnelly SC. Rheumatoid
Arthritis (RA) associated Interstitial Lung Disease (ILD) Eur J Intern Med. 2013;24:597–
603. doi: 10.1016/j.ejim.2013.07.004. [PubMed] [CrossRef] [Google Scholar]

21. Saketkoo L, Espinoza L. Rheumatoid arthritis interstitial lung disease:

mycophenolate mofetil as an antifibrotic and disease-modifying anti rheumatic drug.
Arch Intern Med. 2008;168:1718–9. doi: 10.1001/archinte.168.15.1718. [PubMed]
[CrossRef] [Google Scholar]

22. Atkins S, Turesson C, Myers J, Tazelaar H, Ryu J, Matteson E, et al. Morphologic and
quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated
nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum.
2006;54:635–41. doi: 10.1002/art.21758. [PubMed] [CrossRef] [Google Scholar]

23. Yusof MY, Kabia A, Darby M, Lettieri G, Beirne P, Vital EM, et al. Effect of rituximab
on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’
experience at a single centre. Rheumatology (Oxford) 2017;56:1348–57.
doi: 10.1093/rheumatology/kex072. [PMC free article] [PubMed] [CrossRef]
[Google Scholar]

24. Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J. Rituximab-induced lung disease:

a systematic literature review. Eur Resp J. 2010;35:681–7.
doi: 10.1183/09031936.00080209. [PubMed] [CrossRef] [Google Scholar]

25. Soubrier M, Jeannin G, Kemeny J, Tournadre A, Caillot N, Caillaud D, et al.

Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine.
2008;75:362–5. doi: 10.1016/j.jbspin.2007.10.009. [PubMed] [CrossRef] [Google Scholar]

26. Panopoulos S, Sfikakis P. Biological treatments and connective tissue disease

associated interstitial lung disease. Curr Opin Pulmon Med. 2011;17:362–7.
doi: 10.1097/MCP.0b013e3283483ea5. [PubMed] [CrossRef] [Google Scholar]
27. Mori S, Imamura F, Kiyofuji C, Sugimoto M. Development of interstitial pneumonia
in a rheumatoid arthritis patient treated with infliximab, an antitumor necrosis factor
alpha-neutralizing antibody. Mod Rheumatol. 2006;16:251–5. doi: 10.3109/s10165-006-
0491-5. [PubMed] [CrossRef] [Google Scholar]

28. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Post

marketing surveillance of the safety profile of infliximab in 5000 Japanese patients
with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
doi: 10.1136/ard.2007.072967. [PubMed] [CrossRef] [Google Scholar]

29. Yamazaki H, Isogai S, Sakurai T, Nagasaka K. A case of adalimumab-associated

interstitial pneumonia with rheumatoid arthritis. Mod Rheumatol. 2010;20:518–21.
doi: 10.3109/s10165-010-0308-4. [PubMed] [CrossRef] [Google Scholar]

30. Hadjinicolaou A, Nisar M, Bhagat S, Parfrey H, Chilvers E, Ostor A. Noninfectious

pulmonary complications of newer biological agents for rheumatic diseases-a
systematic literature review. Rheumatology (Oxford) 2011;50:2297–305.
doi: 10.1093/rheumatology/ker289. [PubMed] [CrossRef] [Google Scholar]

31. Pearce F, Johnson S, Courtney P. Interstitial lung disease following certolizumab

pegol. Rheumatology (Oxford) 2012;51:578–80. doi: 10.1093/rheumatology/ker309.
[PubMed] [CrossRef] [Google Scholar]

32. Ramos-Casals M, Brito-Zeron P, Munoz S, Soria N, Galiana D, Bertolaccini L, et al.

Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
Medicine (Baltimore) 2007;86:242–51. doi: 10.1097/MD.0b013e3181441a68. [PubMed]
[CrossRef] [Google Scholar]

33. Dixon W, Hyrich K, Watson K, Lunt M, Symmons D. Influence of anti-TNF therapy

on mortality in patients with rheumatoid arthritis associated interstitial lung disease:
results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis.
2010;69:1086–91. doi: 10.1136/ard.2009.118935. [PMC free article] [PubMed] [CrossRef]
[Google Scholar]

34. Herrinton L, Harrold L, Liu L, Raebel M, Taharka A, Winthrop K, et al. Association

between anti-TNF-α therapy and interstitial lung disease. Pharmacoepidemiol Drug Saf.
2013;22:394–402. doi: 10.1002/pds.3409. [PMC free article] [PubMed] [CrossRef]
[Google Scholar]

35. Horai Y, Miyamura T, Shimada K, Takahama S, Minami R, Yamamoto M, et al.

Eternacept for the treatment of patients with rheumatoid arthritis and concurrent
interstitial lung disease. J Clin Pharm Ther. 2012;37:117–21. doi: 10.1111/j.1365-
2710.2010.01234.x. [PubMed] [CrossRef] [Google Scholar]

36. Olivas-Flores E, Bonilla-Lara D, Gamez-Nava J, Rocha-Muñoz A, GonzalezLopez L.

Interstitial lung disease in rheumatoid arthritis: current concepts in pathogenesis,
diagnosis and therapeutics. World J Rheumatol. 2015;5:1–22. doi: 10.5499/wjr.v5.i1.1.
[CrossRef] [Google Scholar]

37. Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL. Incidence and
complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept
and anti-tumor necrosis factor α agent, a retrospective cohort study. Arthritis Res Ther.
2015;17:319. doi: 10.1186/s13075-015-0835-7. [PMC free article] [PubMed] [CrossRef]
[Google Scholar]

38. Mera-Varela A, Perez-Pampin E. Abatacept therapy in rheumatoid arthritis with

interstitial lung disease. J Clin Rheumatol. 2014;20:445–6.
doi: 10.1097/RHU.0000000000000084. [PubMed] [CrossRef] [Google Scholar]
39. Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS
and biologic agents in rheumatoid arthritis: a systematic literature review. Semin
Arthritis Rheum. 2014;43:613–26. doi: 10.1016/j.semarthrit.2013.09.005. [PubMed]
[CrossRef] [Google Scholar]

40. Gauhar UA, Gaffo AL, Alarcón GS. Pulmonary manifestations of rheumatoid
arthritis. Semin Respir Crit Care Med. 2007;28:430–40. doi: 10.1055/s-2007-985664.
[PubMed] [CrossRef] [Google Scholar]

Articles from European Journal of Rheumatology are provided here courtesy of AVES